Cardiovascular diseases (CVD) and cancer are the major causes of mortality and morbidity all over worldwide. Indeed, both diseases share common risk factors such as lifestyle and ageing, and common pathophysiological mechanisms including inflammation, neuro-hormonal activation, oxidative stress, clonal haematopoiesis and a dysfunctional immune system. An intersection of cardiology and oncology is increasingly recognized, not only because of the toxic effects of cancer or anti-cancer therapeutics on the cardiovascular system but because both diseases are bidirectionally linked. Although epidemiological studies are still in debate, preclinical studies have shown that myocardial infarction, pathological hypertrophic cardiomyopathy and heart failure are prone to develop cancer. Furthermore, some of the cancer markers can estimate CV mortality and CVD.
A better understanding and early diagnosis of CVD and cancer development are critical to delivering timely and targeted prevention strategies and to reduce the world healthcare economic burden. Moreover, clinical awareness is essential to optimize treatment strategies of patients having developed cancer with a history of CVD.
In particular, this special issue mainly invites contributions that report on the following issues in cardio-oncology:
1) Cancer Risk in the patients with CVD, population studies.
2) A meta-analysis and systematic review of whether heart failure increases the risk of incident cancer.
3) Common mechanism for heart failure and development of cancer in patients with heart failure.
4) Common risk factors for cancer and cardiovascular diseases (e.g., smoking, metabolic syndrome, irradiation, age, air pollution, and environmental toxins).
5) Common genetic predisposition for heart failure and cancer.
6) Tumour biomarkers in prediction of cardiovascular events and mortality.
7) Personalized medicine in cardio-oncology: the role of induced pluripotent stem cells.
8) CVD induced tumour development in preclinical mice models.
Cardiovascular diseases (CVD) and cancer are the major causes of mortality and morbidity all over worldwide. Indeed, both diseases share common risk factors such as lifestyle and ageing, and common pathophysiological mechanisms including inflammation, neuro-hormonal activation, oxidative stress, clonal haematopoiesis and a dysfunctional immune system. An intersection of cardiology and oncology is increasingly recognized, not only because of the toxic effects of cancer or anti-cancer therapeutics on the cardiovascular system but because both diseases are bidirectionally linked. Although epidemiological studies are still in debate, preclinical studies have shown that myocardial infarction, pathological hypertrophic cardiomyopathy and heart failure are prone to develop cancer. Furthermore, some of the cancer markers can estimate CV mortality and CVD.
A better understanding and early diagnosis of CVD and cancer development are critical to delivering timely and targeted prevention strategies and to reduce the world healthcare economic burden. Moreover, clinical awareness is essential to optimize treatment strategies of patients having developed cancer with a history of CVD.
In particular, this special issue mainly invites contributions that report on the following issues in cardio-oncology:
1) Cancer Risk in the patients with CVD, population studies.
2) A meta-analysis and systematic review of whether heart failure increases the risk of incident cancer.
3) Common mechanism for heart failure and development of cancer in patients with heart failure.
4) Common risk factors for cancer and cardiovascular diseases (e.g., smoking, metabolic syndrome, irradiation, age, air pollution, and environmental toxins).
5) Common genetic predisposition for heart failure and cancer.
6) Tumour biomarkers in prediction of cardiovascular events and mortality.
7) Personalized medicine in cardio-oncology: the role of induced pluripotent stem cells.
8) CVD induced tumour development in preclinical mice models.
